24.有關C型肝炎預防與治療，下列敘述何者正確？
(A)C型肝炎（+）的母親所生的小孩要給與C型肝炎治療藥品
(B)感染C型肝炎的男性，建議性伴侶要施打hepatitis C vaccine預防
(C)有C型肝炎且免疫功能不全病人常合併有A型肝炎
(D)C型肝炎病人若肌酸酐廓清率（ClCr）＜50 mL/min時，不建議使用ribavirin

C型肝炎
->C型肝炎母親垂直給小孩機率只有6%

->C型肝炎無疫苗(A.B型肝炎才有疫苗)

->若CrCl <50 不建議使用Ribavirin

->小於18yrs 不建議使用Ribavirin

->Ribavirin不能單獨使用

(B)目前無C型肝炎疫苗，因為相較A、B型肝炎病毒，突變率高，對甲有效，傳給乙後突變則無效

4.下列何者最適合治療C型肝炎？ 
(A)interferon + entecavir
(B)interferon + adefovir
(C)pegylated interferon + ribavirin
(D)pegylated interferon + lamivudine 

(a)

The main strategy for reducing the risk of vertical HCV transmission is identifying and treating HCV-infected women prior to conception.

The safety and efficacy of direct-acting antiviral agents during pregnancy and in neonates have not yet been assessed, and these agents should not be used in such populations.

The treatment of HCV in children is discussed in detail elsewhere.

Children <12 years — For virtually all children younger than 12 years of age with HCV infection, we suggest deferring treatment until an all-oral DAA regimen is available (algorithm 1) .

These individuals may become eligible for DAA treatment by waiting until after their 12th birthday

Ribavirin

1. 因為ribavirin單一療法對治療C型肝炎無效，故不可單獨投與ribavirin膠囊。 
2. Ribavirin必須與peginterferon alfa (1.5mcg/公斤/週)或interferon alfa (三百萬國際單位 (MIU)，每週3次 (TIW)) 併用治療。選擇以何種併用的方式，則視病人個別的狀況而定。 
3. Ribavirin膠囊與peginterferon alfa溶液併用： Ribavirin的劑量依據病人的體重而定。Ribavirin膠囊每日分二次給與並與食物一同服用 (早晨和傍晚)。

病人必須達18歲以上且患有代償性肝病。